Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

October 31, 2016

Conditions
Cystic FibrosisCystic Fibrosis Pulmonary ExacerbationPseudomonas Aeruginosa Infection
Interventions
DRUG

Ceftolozane/Tazobactam

1 hour intravenous infusion

Trial Locations (4)

19134

St. Christopher's Hospital for Children, Philadelphia

27599

University of North Carolina Medical Center, Chapel Hill

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

06102

Hartford Hospital, Hartford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

collaborator

Indiana University Health

OTHER

collaborator

University of North Carolina

OTHER

collaborator

St. Christopher's Hospital for Children

OTHER

lead

Joseph L. Kuti, PharmD

OTHER